Brentuximab Vedotin Approved for Two Rare Lymphomas

FDA has approved brentuximab vedotin (Adcetris®) for the treatment of adults who have been treated previously for either primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides, two rare lymphomas that start as rashes on the skin.

Cancer Currents: An NCI Cancer Research Blog